Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.38, $0.30 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.77 billion versus the consensus estimate of $2.69 billion.

GUIDANCE:

Vertex Pharma sees FY2024 revenue of $10.8-10.9 billion, versus the consensus of $10.759 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.